SLIM-1 Data: Semaglutide Implant Matches Wegovy Weight Loss With Zero Treatment-Related AEs
VANI sits 27% above its 52-week low of $0.923.
Summary
Vivani's SLIM-1 Phase 1 readout is the binary event the stock has been waiting on, and it came in clean. None of the 10 NPM-139 implant subjects had treatment-related adverse events versus 5 of 10 in the Wegovy control group, and the implant produced no rapid drug spikes — peak levels at roughly 16 days versus about 2.4 days for weekly Wegovy. Weight loss was essentially a tie: 0.79% for NPM-139 versus 0.82% for Wegovy over the four-week study, with no serious adverse events and uncomplicated insertions and removals. The company will push NPM-139 into a Phase 2 dose-ranging weight maintenance trial anticipated to begin in 2027, and will explore GLP-1-naïve patients given the tolerability profile. This lands the day after the Q3 report showing a $7.3M quarterly loss and alongside the 10-Q's going-concern warning and cash runway ending Q1 2027 — so the data validates the platform but the balance sheet still needs funding before that Phase 2 starts.
At the time of this announcement, VANI was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101.9M. The 52-week trading range was $0.92 to $1.66. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.